Differences between right-sided and left-sided intestinal cancers

Abstract

Abstract:Decreasing trend has occurred in incidence of colorectal cancer in developed countries. A shift from left to right in location of colorectal cancer has been recognized, which may be associated with colonoscopy screening, aging population, diet structure modification, increased incidence of cancer and diabetes. Factors including sex, race and education may also play a role to some extent. Rightsided intestinal cancers have higher proportion of poor differentiation, terminal stage and mucinous component. Complications and second primary intestinal cancer are more common in rightsided intestinal cancers. Leftsided intestinal cancers tend to be well differentiated and at relatively early stage at diagnosis. With respect to molecular mechanism, rightsided cancers are associated with mismatch repair system, while leftsided cancers are related to p53 mutation. Based on the differences in clinicopathology and genetics, it′s implied that leftsided and rightsided intestinal cancers may belong to two different kind of disease. It′s suggested that attentions should be paid differently according to their respective characteristics in clinical practice and trials.

Key words:Colorectal neoplasms,Disease attributes,Neoplasm site

Yang-Jiao-；Fu-Jian-Fei-；Zhong-Xian-；Yuan-Ying. Differences between right-sided and left-sided intestinal cancers[J]. Journal of International Oncology, 2015, 42(4): 305-308.

References

［1］ Xu AG, Yu ZJ, Jiang B, et al. Colorectal cancer in Guangdong Province of China: A demographic and anatomic survey［J］. World J Gastroentero, 2010, 16(8): 960965. ［2］ Phipps AL, Scoggins J, Rossing MA, et al. Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 19752007［J］. Am J Public Health, 2012, 102(9): 17911797. ［3］ Meza R, Jeon J, Renehan AG, et al. Colorectal cancer incidence trends in the United States and United kingdom: evidence of right to leftsided biological gradients with implications for screening［J］. Cancer Res, 2010, 70(13): 54195429. ［4］ Brenner H, Hoffmeister M, Arndt V, et al. Protection from right and leftsided colorectal neoplasms after colonoscopy: populationbased study［J］. J Natl Cancer Inst, 2010, 102(2): 8995. ［5］ Benedix F, Schmidt U, Mroczkowski P, et al. Colon carcinoma—classification into right and left sided cancer or according to colonic subsite?—Analysis of 29,568 patients［J］. Eur J Surg Oncol, 2011, 37(2): 134139. ［6］ Collins BD. Risk of proximal colonic neoplasms in asymptomatic adults older than 50 years found to have distal hyperplastic polyps on routine colorectal cancer screening［J］. Perm J, 2010, 14(2): 1116. ［7］ Annema N, Heyworth JS, McNaughton SA, et al. Fruit and vegetable consumption and the risk of proximal colon, distal colon, and rectal cancers in a casecontrol study in Western Australia［J］. J Am Diet Assoc, 2011, 111(10): 14791490. ［8］ Leufkens AM, Van Duijnhoven FJ, Boshuizen HC, et al. Educational level and risk of colorectal cancer in EPIC with specific reference to tumor location［J］. Int J Cancer, 2012, 130(3): 622630. ［9］ Ghazi S, Lindforss U, Lindberg G, et al. Analysis of colorectal cancer morphology in relation to sex, age, location, and family history［J］. J Gastroenterol, 2012, 47(6): 619634. ［10］米登海,王燕慧. 阿司匹林与肿瘤防治［J］. 国际肿瘤学杂志, 2010, 37(6): 435437. ［11］ Rothwell PM, Wilson M, Elwin CE, et al. Longterm effect of aspirin on colorectal cancer incidence and mortality: 20year followup of five randomised trials［J］. Lancet, 2010, 376(9754): 17411750. ［12］ Brandstedt J, Wangefjord S, Nodin B, et al. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study［J］. Biol Sex Differ, 2012, 3(1): 23. ［13］ Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right and leftsided colon cancer: differences in epidemiology, perioperative course, histology, and survival［J］. Dis Colon Rectum, 2010, 53(1): 5764. ［14］ Kaku E, Oda Y, Murakami Y, et al. Proportion of flat and depressedtype and laterally spreading tumor among advanced colorectal neoplasia［J］. Clin Gastroenterol H, 2011, 9(6): 503508. ［15］ Hernandez MN, Sussman DA, Lee DJ, et al. Trends in colorectal cancer among hispanics by stage and subsite location: 19892006［J］. Clin Transl Gastroenterol, 2012, 3: e21. ［16］ Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer［J］. Ann Oncol, 2013, 24(10): 25542559. ［17］ Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage Ⅲ colon cancer from a randomized trial of FOLFOXbased adjuvant chemotherapy［J］. J Clin Oncol, 2013, 31(29): 36643672. ［18］ Cho YK, Kim HC, Kim SH, et al. Locationrelated differences in sporadic microsatellite unstable colorectal cancer［J］. Dig Liver Dis, 2010, 42(9): 611615. ［19］ Phipps AI, Lindor NM, Jenkins MA, et al. Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry［J］. Dis Colon Rectum, 2013, 56(8): 937944. ［20］ Zhao Y, Oki E, Ando K, et al. The impact of a highfrequency microsatellite instability phenotype on the tumor locationrelated genetic differences in colorectal cancer［J］. Cancer Genet Cytogenet, 2010, 196(2): 133139. ［21］ FariaSarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage Ⅱ and stage Ⅲ colon cancer patients［J］. Ann Oncol, 2010, 21(12): 23962402. ［22］ Pai RK, Jayachandran P, Koong AC, et al. BRAFmutated, microsatellitestable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features［J］. Am J Surg Pathol, 2012, 36(5): 744752. ［23］ Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis［J］. Dis Colon Rectum, 2012, 55(2): 128133. ［24］ Clancy C, Burke JP, Kalady MF, et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and metaanalysis［J］. Colorectal Dis, 2013, 15(12): e711e718. ［25］ Eklf V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer［J］. Br J Cancer, 2013, 108(10): 21532163. ［26］ Papagiorgis PC, Zizi AE, Tseleni S, et al. The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location［J］. Oncol Lett, 2012, 3(5): 11291135.

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang.Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang.Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong.Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer[J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu.Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment[J]. Journal of International Oncology, 2022, 49(8): 490-493.